Table 3 Quality assessment results
From: Budget impact analysis of breast cancer medications: a systematic review
Study | Perspective | Target population estimate | Time horizon | Hypothetical scenario | Comparator | Framework description | Data collection | Validation | Sensitivity analysis | Total (%) |
|---|---|---|---|---|---|---|---|---|---|---|
Ivanov et al. [40] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Elsamany et al. [37] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 100 |
Pouwels et al. [27] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 88.9 | |
Genuino et al. [38] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 88.9 | |
Avxentyev et al. [41] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 88.9 | |
Lee et al. [28] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 100 |
Mistry et al. [34] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 88.9 | |
Clarke et al. [33] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Cesarec et al. [26] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Lewis et al. [39] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Benjamin et al. [30] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 100 |
Xie et al. [43] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 100 |
Purmonen et al. [31] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Ho et al. [36] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 88.9 | |
Neyt et al. [32] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Millar et al. [42] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 88.9 | |
Marchetti et al. [29] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 77.8 | ||
Total (%) | 94.1 | 64.7 | 100 | 88.2 | 82.4 | 100 | 100 | 52.9 | 100 | 86.9 |